Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLA treatment of minimal hepatic encephalopathy and the brain-muscle axis
2012-003817-32Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of l-ornithine l-aspartate in hepatic encephalopathy (HE), sponsored by Imperial College London. Primary endpoint: Improvement in mental state. Started Nov 2012; status: completed.
02
Drugs
l-ornithine l-aspartate
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on 2012-003817-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003817-32.